Journal article

Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

Christian Anholm, Preman Kumarathurai, Amirsalar Samkani, Lene R Pedersen, Raymond C Boston, Olav W Nielsen, Ole P Kristiansen, Mogens Fenger, Sten Madsbad, Ahmad Sajadieh, Steen B Haugaard

DIABETES OBESITY & METABOLISM | WILEY | Published : 2019

Abstract

Elevated levels of non-esterified fatty acids (NEFA) play a role in insulin resistance, impaired beta-cell function and they are a denominator of the abnormal atherogenic lipid profile that characterizes obese patients with type 2 diabetes (T2DM). We hypothesized that the GLP-1 receptor agonist liraglutide, in combination with metformin, would reduce lipolysis. In a randomized, double-blind, placebo-controlled, cross-over trial, 41 T2DM patients with coronary artery disease were randomized and treated with liraglutide-metformin vs placebo-metformin during 12- + 12-week periods with a wash-out period of at least 2 weeks before and between the intervention periods. NEFA kinetics were estimated..

View full abstract

University of Melbourne Researchers